Histochemical effects of bisphosphonate on osteocytic lacunar-canalicular system
| Project/Area Number |
15H06002
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
Kanako Tsuboi 北海道大学, 大学病院, 医員 (50754610)
|
|---|
| Project Period (FY) |
2015-08-28 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 骨細胞 / 糖尿病 / ビスホスホネート |
|---|
| Outline of Final Research Achievements |
We have examined if bisphosphonate would affect osteoblasts/osteocytes, and also if diabates mellitus would worsen the histological features of osteocytes and bone matrix using in SDT fatty rats mimicking diabates mellitus. Stimulated emission depletion microscopy successfully visualized three dimensional structures of actin filaments within the cytoplasmic processes of osteocytes. SDT fatty rats revealed broad un-mineralized bone matrix including many irregularly-arranged DMP-1-/OCN-immunopositive osteocytes, as well as many α-SMA-positive/CD31-reactive blood vessels in the diaphyseal bone marrow. Taken together, diabetes mellitus appears to influence the histological aspects of osteocytes and vascular endothelial cells.
|
Report
(3 results)
Research Products
(10 results)
-
[Journal Article] Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes.2016
Author(s)
Tsuboi K., Hasegawa T., Yamamoto T., Sasaki M., Hongo H., Oda K., Michigami T., Li M., Freitas PHL., Kitagawa Y., Amizuka N.
-
Journal Title
Histochemistry and Cell Biology
Volume: 146巻3号
Issue: 3
Pages: 337-350
DOI
Related Report
Peer Reviewed / Int'l Joint Research / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
